Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study
Year: 2005
Type: article
Study design: Observational Study
Abstract: Previous studies of recipients of hematopoietic stem-cell transplants suggest that graft-versus-host disease (GVHD) and its therapy may increase the risk for solid cancers, particularly squamous-cell carcinomas (SCCs) of the buccal cavity and skin. However, the importance and magnitude of these associations are not well characterized. We conducted a case-control study of 183 patients with posttransplantation solid cancers (58 SCCs, 125 non-SCCs) and 501 matched control patients within a cohort of 24,011 patients who underwent hematopoietic stem-cell transplantation (HSCT) at 215 centers worldwide. Our results showed that chronic GVHD and its therapy were strongly related to the risk for SCC, whereas no increase in risk was found for non-SCCs. Major risk factors for the development of SCC were long duration of chronic GVHD therapy (P < .001); use of azathioprine, particularly when combined with cyclosporine and steroids (P < .001); and severe chronic GVHD (P = .004). Given that most patients who received prolonged immunosuppressive therapy and those with severe chronic GVHD were also treated with azathioprine, the independent effects of these factors could not be evaluated. Additional analyses determined that prolonged immunosuppressive therapy and azathioprine use were also significant risk factors for SCC of the skin and of the oral mucosa. These data provide further encouragement for strategies to prevent chronic GVHD and for the development of more effective and less carcinogenic treatment regimens for patients with moderate or severe chronic GVHD. Our results also suggest that clinical screening for SCC is appropriate among patients exposed to persistent chronic GVHD, prolonged immunosuppressive therapy, or both.
Source: Blood
Institutions: National Institutes of Health, University of Washington, Medical College of Wisconsin, Fred Hutch Cancer Center, National Cancer Institute, Hôpital Saint-Louis, Armed Forces Institute of Pathology, Division of Cancer Epidemiology and Genetics, Laboratoire d'hématologie, University of California, Berkeley
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Lynde and Harry Bradley Foundation, Amgen, Biogen, Celgene, Blue Cross and Blue Shield Association, IC Design Education Center, National Institutes of Health, Agency for Healthcare Research and Quality, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Allergy and Infectious Diseases
Awards: G2552402614, G313299077, CANCER FOLLOWING BONE MARROW TRANSPLANTATION, Stem Cell Transplantation: Basic/Clinical Research, LONG-TERM OUTCOME OF BLOOD AND MARROW TRANSPLANTATION, G840000828, CANCER FOLLOWING BONE MARROW TRANSPLANTATION, Cancer Center Support Grant, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research, Adult Leukemia Research Center
OpenAlex ID: W2019744886
